Td Asset Management Inc Immuneering Corp Transaction History

Td Asset Management Inc

$102 Billion
Q1 2025

A detailed history of Td Asset Management Inc transactions in Immuneering Corp stock. As of the latest transaction made, Td Asset Management Inc holds 71,066 shares of IMRX stock, worth $284,974. This represents 0.0% of its overall portfolio holdings.

Number of Shares

71,066

Previous 150,876 52.9%

Holding current value

$284,974

Previous $331,000 67.37%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 07, 2025	SELL	$1.46 - $2.36 $116,522 - $188,351	-79,810 Reduced 52.9%	71,066 $108,000
Q1 2024 May 08, 2024	SELL	$1.91 - $7.32 $89,770 - $344,040	-47,000 Reduced 23.75%	150,876 $436,000
Q4 2023 Feb 12, 2024	SELL	$4.84 - $8.44 $419,144 - $730,904	-86,600 Reduced 30.44%	197,876 $1.45 Million
Q3 2023 Oct 27, 2023	BUY	$7.21 - $10.68 $1.03 Million - $1.52 Million	142,238 Added 100.0%	284,476 $2.18 Million
Q2 2023 Aug 09, 2023	SELL	$6.49 - $13.36 $12,103 - $24,916	-1,865 Reduced 1.29%	142,238 $1.44 Million
Q1 2023 May 10, 2023	SELL	$3.78 - $10.38 $9,869 - $27,102	-2,611 Reduced 1.78%	144,103 $1.4 Million
Q4 2022 Feb 06, 2023	SELL	$4.09 - $15.0 $3,873 - $14,205	-947 Reduced 0.64%	146,714 $711,000
Q2 2022 Aug 04, 2022	BUY	$3.89 - $7.81 $102,929 - $206,652	26,460 Added 21.83%	147,661 $799,000
Q1 2022 May 10, 2022	BUY	$6.47 - $16.99 $562,275 - $1.48 Million	86,905 Added 253.4%	121,201 $784,000
Q3 2021 Nov 09, 2021	BUY	$17.0 - $32.84 $583,032 - $1.13 Million	34,296 New	34,296 $911,000

Others Institutions Holding IMRX

# of Institutions

Shares Held

4.78M

Call Options Held

Put Options Held

View Full List

About Immuneering Corp

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $106M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

More about IMRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.

Account

Td Asset Management Inc Immuneering Corp Transaction History